SK Biopharmaceuticals Discusses End-to-End Strategy for Cenobamate with Global Partners

Consecutive Hosting of the Commercial Alliance Meeting
and the First-Ever Medical Alliance Meeting

SK Biopharmaceuticals announced on December 8 that, during the 2025 American Epilepsy Society (AES) conference held in Atlanta, Georgia, USA, it hosted a 'Commercial Alliance Meeting' on December 5 (local time) and a 'Medical Alliance Meeting' on December 6, together with its global partners.

SK Biopharmaceuticals' decision to hold both events consecutively this year was a strategic move to closely connect the commercial and medical strategies for cenobamate from an end-to-end perspective, and to further expand its global business and medical collaboration framework. The company has established a collaborative structure that integrates commercialization experience and clinical and medical data by region, thereby strengthening the consistency and speed of its global strategy execution.

Exhibition booth of SK Biopharmaceuticals at the 2025 Epilepsy Conference. SK Biopharmaceuticals

The Commercial Alliance Meeting, held on the first day, brought together nearly 50 participants, including Yu Changho, Head of Strategy at SK Biopharmaceuticals, key personnel from its US subsidiary SK Life Science, and major partners from around the world such as Angelini Pharma in Europe, Ono Pharmaceutical in Japan, and Knight Therapeutics in Canada, totaling seven key global partners.

Now in its second year, the Commercial Alliance Meeting covered topics such as: ▲ the performance and growth trends of cenobamate (brand name XCOPRI®) in the US ▲ the performance and patient adoption status of cenobamate (brand name ONTOZRY®) in Europe ▲ major issues and strategic tasks related to cenobamate. Participants also shared that the direct sales model in the US and key regional commercialization partnerships are organically linked, accelerating the global expansion of the product.

The Medical Alliance Meeting, held on the second day for the first time this year, included the participation of Angelini Pharma and Ono Pharmaceutical. The meeting focused on ▲ clinical and medical experience accumulated since product launches in each country ▲ research strategies and data status ▲ clinical plans for 2026, as part of a review of the global collaboration framework. In particular, SK Biopharmaceuticals presented its R&D strategy and future joint execution plans to strengthen cenobamate's global competitiveness, and engaged in in-depth discussions with its partners on lifecycle management (LCM) strategies for cenobamate, further reinforcing strategic alignment.

Lee Donghoon, CEO of SK Biopharmaceuticals, stated, "This alliance meeting was a meaningful opportunity to comprehensively refine the global strategy for cenobamate and to further specify future expansion plans with our partners. Based on close collaboration with our partners, we will continue to drive patient-centered innovation and sustainable growth."

This content was produced with the assistance of AI translation services.